Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Prasugrel
Overview
What is Prasugrel?
Prasugrel tablets contain prasugrel, a thienopyridine class inhibitor of platelet activation and aggregation mediated by the P2Y ADP receptor. Prasugrel is formulated as the hydrochloride salt, a racemate, which is chemically designated as 5-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride. Prasugrel hydrochloride has the molecular formula CHFNOS•HCl representing a molecular weight of 409.90. The chemical structure of prasugrel hydrochloride is:
Prasugrel hydrochloride is a white to practically white powder. It is freely soluble in methanol, practically insoluble in water.
Prasugrel tablets are available for oral administration as 5 mg or 10 mg elongated hexagonal, film-coated, non-scored tablets, debossed on each side. Each yellow 5 mg tablet is manufactured with 5.49 mg prasugrel hydrochloride, equivalent to 5 mg prasugrel and each beige 10 mg tablet with 10.98 mg prasugrel hydrochloride, equivalent to 10 mg of prasugrel.
Other ingredients include glyceryl behenate, hypromellose, lactose monohydrate, low substituted hydroxypropyl cellulose, mannitol, microcrystalline cellulose, sucrose stearate, titanium dioxide, triacetin, and yellow iron oxide. In addition, the 10 mg tablets contain red iron oxide.
What does Prasugrel look like?
What are the available doses of Prasugrel?
5 mg and 10 mg tablets
What should I talk to my health care provider before I take Prasugrel?
How should I use Prasugrel?
Prasugrel tablets are a P2Y platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows:
Initiate prasugrel tablets treatment as a single 60 mg oral loading dose and then continue at 10 mg orally once daily. Patients taking prasugrel tablets should also take aspirin (75 mg to 325 mg) daily . Prasugrel tablets may be administered with or without food .
Timing of Loading Dose
In the clinical trial that established the efficacy and safety of prasugrel tablets, the loading dose of prasugrel tablets was not administered until coronary anatomy was established in UA/NSTEMI patients and in STEMI patients presenting more than 12 hours after symptom onset. In STEMI patients presenting within 12 hours of symptom onset, the loading dose of prasugrel tablets was administered at the time of diagnosis, although most received prasugrel tablets at the time of PCI . For the small fraction of patients that required urgent CABG after treatment with prasugrel tablets, the risk of significant bleeding was substantial.
Although it is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation, in a trial of 4033 NSTEMI patients, no clear benefit was observed when prasugrel tablets loading dose was administered prior to diagnostic coronary angiography compared to at the time of PCI; however, risk of bleeding was increased with early administration in patients undergoing PCI or early CABG.
Dosing in Low Weight Patients
Compared to patients weighing ≥60 kg, patients weighing <60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10 mg once daily maintenance dose. Consider lowering the maintenance dose to 5 mg in patients <60 kg. The effectiveness and safety of the 5 mg dose have not been prospectively studied .
What interacts with Prasugrel?
Sorry No Records found
What are the warnings of Prasugrel?
Sorry No Records found
What are the precautions of Prasugrel?
Sorry No Records found
What are the side effects of Prasugrel?
Sorry No records found
What should I look out for while using Prasugrel?
Active pathological bleeding
Prior transient ischemic attack or stroke
Hypersensitivity to prasugrel or any component of the product
What might happen if I take too much Prasugrel?
How should I store and handle Prasugrel?
The ASMANEX HFA canister should only be used with the ASMANEX HFA actuator. The ASMANEX HFA actuator should not be used with any other inhalation drug product. Actuators from other products should not be used with the ASMANEX HFA canister.The canister should not be removed from the actuator because the correct amount of medication may not be discharged; the dose counter may not function properly; reinsertion may cause the dose counter to count down by 1 and discharge a puff.The correct amount of medication in each inhalation cannot be ensured after the labeled number of actuations from the canister has been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of actuations has been used (the dose counter will read "0").Store at controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].For best results, the canister should be at room temperature before use. Shake well and remove the cap from the mouthpiece of the actuator before using. Keep out of reach of children. Avoid spraying in eyes.Contents Under Pressure: Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator.The ASMANEX HFA canister should only be used with the ASMANEX HFA actuator. The ASMANEX HFA actuator should not be used with any other inhalation drug product. Actuators from other products should not be used with the ASMANEX HFA canister.The canister should not be removed from the actuator because the correct amount of medication may not be discharged; the dose counter may not function properly; reinsertion may cause the dose counter to count down by 1 and discharge a puff.The correct amount of medication in each inhalation cannot be ensured after the labeled number of actuations from the canister has been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of actuations has been used (the dose counter will read "0").Store at controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].For best results, the canister should be at room temperature before use. Shake well and remove the cap from the mouthpiece of the actuator before using. Keep out of reach of children. Avoid spraying in eyes.Contents Under Pressure: Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator.The ASMANEX HFA canister should only be used with the ASMANEX HFA actuator. The ASMANEX HFA actuator should not be used with any other inhalation drug product. Actuators from other products should not be used with the ASMANEX HFA canister.The canister should not be removed from the actuator because the correct amount of medication may not be discharged; the dose counter may not function properly; reinsertion may cause the dose counter to count down by 1 and discharge a puff.The correct amount of medication in each inhalation cannot be ensured after the labeled number of actuations from the canister has been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of actuations has been used (the dose counter will read "0").Store at controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].For best results, the canister should be at room temperature before use. Shake well and remove the cap from the mouthpiece of the actuator before using. Keep out of reach of children. Avoid spraying in eyes.Contents Under Pressure: Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator.The ASMANEX HFA canister should only be used with the ASMANEX HFA actuator. The ASMANEX HFA actuator should not be used with any other inhalation drug product. Actuators from other products should not be used with the ASMANEX HFA canister.The canister should not be removed from the actuator because the correct amount of medication may not be discharged; the dose counter may not function properly; reinsertion may cause the dose counter to count down by 1 and discharge a puff.The correct amount of medication in each inhalation cannot be ensured after the labeled number of actuations from the canister has been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of actuations has been used (the dose counter will read "0").Store at controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].For best results, the canister should be at room temperature before use. Shake well and remove the cap from the mouthpiece of the actuator before using. Keep out of reach of children. Avoid spraying in eyes.Contents Under Pressure: Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator.The ASMANEX HFA canister should only be used with the ASMANEX HFA actuator. The ASMANEX HFA actuator should not be used with any other inhalation drug product. Actuators from other products should not be used with the ASMANEX HFA canister.The canister should not be removed from the actuator because the correct amount of medication may not be discharged; the dose counter may not function properly; reinsertion may cause the dose counter to count down by 1 and discharge a puff.The correct amount of medication in each inhalation cannot be ensured after the labeled number of actuations from the canister has been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of actuations has been used (the dose counter will read "0").Store at controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].For best results, the canister should be at room temperature before use. Shake well and remove the cap from the mouthpiece of the actuator before using. Keep out of reach of children. Avoid spraying in eyes.Contents Under Pressure: Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator.The ASMANEX HFA canister should only be used with the ASMANEX HFA actuator. The ASMANEX HFA actuator should not be used with any other inhalation drug product. Actuators from other products should not be used with the ASMANEX HFA canister.The canister should not be removed from the actuator because the correct amount of medication may not be discharged; the dose counter may not function properly; reinsertion may cause the dose counter to count down by 1 and discharge a puff.The correct amount of medication in each inhalation cannot be ensured after the labeled number of actuations from the canister has been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of actuations has been used (the dose counter will read "0").Store at controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].For best results, the canister should be at room temperature before use. Shake well and remove the cap from the mouthpiece of the actuator before using. Keep out of reach of children. Avoid spraying in eyes.Contents Under Pressure: Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator.Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Valacyclovir Tablets, USP are available containing valacyclovir hydrochloride, USP equivalent to 500 mg or 1 gram of valacyclovir.The 500 mg tablets are white, film-coated, oval shaped tablets imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4275-93bottles of 30 tabletsNDC 0378-4275-77bottles of 90 tabletsNDC 0378-4275-05bottles of 500 tabletsThe 1 gram tablets are white, film-coated, oval shaped tablets with a partial break line on both sides. They are imprinted with in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4276-93bottles of 30 tabletsNDC 0378-4276-77bottles of 90 tabletsNDC 0378-4276-05bottles of 500 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y class of ADP receptors on platelets.
Non-Clinical Toxicology
Active pathological bleedingPrior transient ischemic attack or stroke
Hypersensitivity to prasugrel or any component of the product
Apraclonidine should not be used in patients receiving MAO inhibitors (see ). Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of apraclonidine ophthalmic solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered. Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with apraclonidine can lead to a reduction in IOP lowering effect. No data on the level of circulating catecholamines after apraclonidine withdrawal are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy. Systemic clonidine may inhibit the production of catecholamines in response to insulin-induced hypoglycemia and mask the signs and symptoms of hypoglycemia.
Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised. Patients using cardiovascular drugs concurrently with apraclonidine ophthalmic solution should have pulse and blood pressure frequently monitored. Caution should be exercised with simultaneous use of clonidine and other similar pharmacologic agents.
Thienopyridines, including prasugrel, increase the risk of bleeding. With the dosing regimens used in TRITON-TIMI 38, TIMI (Thrombolysis in Myocardial Infarction) Major (clinically overt bleeding associated with a fall in hemoglobin ≥5 g/dL, or intracranial hemorrhage) and TIMI Minor (overt bleeding associated with a fall in hemoglobin of ≥3 g/dL but <5 g/dL) bleeding events were more common on prasugrel than on clopidogrel . The bleeding risk is highest initially, as shown in Figure 1 (events through 450 days; inset shows events through 7 days). Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, PCI, CABG, or other surgical procedures even if the patient does not have overt signs of bleeding. Do not use prasugrel in patients with active bleeding, prior TIA or stroke . Other risk factors for bleeding are:
Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7 to 10 days), so withholding a dose will not be useful in managing a bleeding event or the risk of bleeding associated with an invasive procedure. Because the half-life of prasugrel’s active metabolite is short relative to the lifetime of the platelet, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 6 hours of the loading dose or 4 hours of the maintenance dose may be less effective.
The following serious adverse reactions are also discussed elsewhere in the labeling:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).